Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 15/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 5/20 | 0.34 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.34 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.34 |
| ▸ | RPS6KB2 | Q9UBS0 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21726330 | 0.85 | MAP4K1 (0.34) | FGFR4FGFR2CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL21726323 | 0.77 | FGFR4 (0.40) | FGFR4FGFR1FGFR2FGFR3RPS6KB2 | |
| SCHEMBL21726306 | 0.76 | ABL1 (0.44) | FGFR3HTR2AHTR2CCYP11B1CYP11B2 | |
| SCHEMBL21726329 | 0.74 | LRRK2 (0.34) | FGFR4FGFR1FGFR2FGFR3HTR2A | |
| SCHEMBL17531042 | 0.70 | RXRA (0.48) | FGFR4FGFR1FGFR2FGFR3RPS6KB2 | |
| SCHEMBL15618399 | 0.68 | FGFR4 (0.63) | FGFR4FGFR1FGFR2FGFR3RPS6KB2 | |
| SCHEMBL17530560 | 0.67 | FGFR1 (0.51) | FGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL20437600 | 0.66 | KMO (0.44) | FGFR4FGFR1CYP11B1CYP11B2 | |
| SCHEMBL22753215 | 0.66 | HTR2A (0.49) | HTR2AHTR2CCYP19A1CYP11B1CYP11B2 | |
| SCHEMBL29385382 | 0.64 | FGFR4 (0.69) | FGFR4FGFR1FGFR2FGFR3RPS6KB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10562900-B2 | Indazole compounds as FGFR kinase inhibitor, preparation and use thereof | SHANGHAI HAIHE PHARMACEUTICAL CO., LTD. (CN) | 2020-02-18 | — | — | US | disclosed |
| US-20170275291-A1 | INDAZOLE COMPOUNDS AS FGFR KINASE INHIBITOR, PREPARATION AND USE THEREOF | SHANGHAI HAIHE PHARMACEUTICAL CO., LTD. (CN) | 2017-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562900-B2 | Indazole compounds as FGFR kinase inhibitor, preparation and use thereof | FGFR1, FGFR2, FGFR3 | FGFR4 4/4885FGFR1 1/4885FGFR2 2/4885 |
| US-20170275291-A1 | INDAZOLE COMPOUNDS AS FGFR KINASE INHIBITOR, PREPARATION AND USE THEREOF | FGFR1, FGFR2, FGFR3 | FGFR4 4/4885FGFR1 1/4885FGFR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.